#BEGIN_DRUGCARD DB04465

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
63-42-3

# ChEBI_ID:
36219

# Chemical_Formula:
C12H22O11

# Chemical_IUPAC_Name:
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-{[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Sweetening Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1.95E+005 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Lactose

# HET_ID:
LAT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11?,12+/m1/s1

# InChI_Key:
InChIKey=GUBGYTABKSRVRQ-QKKXKWKRSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00243

# KEGG_Drug_ID:
D00046

# LIMS_Drug_ID:
4465

# Mechanism_Of_Action:
Not Available

# Melting_Point:
201-202 °C

# Molecular_Weight_Avg:
342.2965

# Molecular_Weight_Mono:
342.116211546

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JYN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450161

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-3

# Predicted_LogS:
0.23

# Predicted_Water_Solubility:
5.86e+02 g/l

# Primary_Accession_No:
DB04465

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02005

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:21 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
GLT6D1

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7011

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Glycosyltransferase 6 domain-containing protein 1

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q7Z4J2

# Drug_Target_1_SwissProt_Name:
GL6D1_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GLTP

# Drug_Target_2_GenBank_ID_Gene:
AF209704

# Drug_Target_2_GenBank_ID_Protein:
6959686

# Drug_Target_2_GeneCard_ID:
GLTP

# Drug_Target_2_Gene_Name:
GLTP

# Drug_Target_2_Gene_Sequence:
>630 bp
ATGGCGCTGCTGGCGGAGCACTTGCTGAAGCCGCTGCCCGCGGACAAGCAGATCGAGACC
GGGCCCTTCCTCGAGGCGGTGTCCCACCTGCCGCCCTTCTTCGATTGCCTTGGGTCCCCA
GTGTTTACTCCCATCAAGGCAGACATAAGCGGCAACATCACGAAAATCAAAGCTGTGTAC
GACACCAACCCAGCCAAGTTCCGGACCCTGCAGAACATCCTGGAGGTGGAGAAAGAAATG
TATGGAGCAGAGTGGCCCAAAGTAGGGGCCACACTGGCGCTGATGTGGCTGAAAAGAGGC
CTCCGCTTCATCCAGGTCTTCCTCCAGAGCATCTGCGACGGGGAGCGGGACGAGAACCAC
CCCAACCTCATCCGTGTCAACGCCACCAAGGCCTACGAGATGGCCCTCAAGAAGTACCAT
GGCTGGATCGTGCAGAAGATCTTCCAGGCAGCACTGTACGCAGCACCCTATAAGTCTGAC
TTCCTGAAAGCGCTCTCCAAGGGGCAGAATGTTACGGAGGAGGAGTGCCTGGAGAAGATC
CGCCTCTTCCTAGTCAACTACACGGCGACCATCGATGTCATCTACGAGATGTACACCCAG
ATGAACGCTGAGCTCAACTACAAGGTGTAG

# Drug_Target_2_General_Function:
Involved in glycolipid binding

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
HGNC:24867

# Drug_Target_2_HPRD_ID:
16409

# Drug_Target_2_ID:
3382

# Drug_Target_2_Locus:
12q24.11

# Drug_Target_2_Molecular_Weight:
23850

# Drug_Target_2_Name:
Glycolipid transfer protein

# Drug_Target_2_Number_of_Residues:
209

# Drug_Target_2_PDB_ID:
1SX6

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
>Glycolipid transfer protein
MALLAEHLLKPLPADKQIETGPFLEAVSHLPPFFDCLGSPVFTPIKADISGNITKIKAVY
DTNPAKFRTLQNILEVEKEMYGAEWPKVGATLALMWLKRGLRFIQVFLQSICDGERDENH
PNLIRVNATKAYEMALKKYHGWIVQKIFQAALYAAPYKSDFLKALSKGQNVTEEECLEKI
RLFLVNYTATIDVIYEMYTQMNAELNYKV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Accelerates the intermembrane transfer of various glycolipids. Catalyzes the transfer of various glycosphingolipids and glyceroglycolipids between membranes but does not catalyze the transfer of phospholipids. It is possible that it is involved in the intracellular translocation of glucosylceramides

# Drug_Target_2_SwissProt_ID:
Q9NZD2

# Drug_Target_2_SwissProt_Name:
GLTP_HUMAN

# Drug_Target_2_Synonyms:
GLTP

# Drug_Target_2_Theoretical_pI:
7.49

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M11118

# Drug_Target_3_GenBank_ID_Protein:
153000

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
entB

# Drug_Target_3_Gene_Sequence:
>801 bp
ATGTATAAGAGATTATTTATTTCACATGTAATTTTGATATTCGCACTGATATTAGTTATT
TCTACACCCAACGTTTTAGCAGAGAGTCAACCAGATCCTAAACCAGATGAGTTGCACAAA
TCGAGTAAATTCACTGGTTTGATGGAAAATATGAAAGTTTTGTATGATGATAATCATGTA
TCAGCAATAAACGTTAAATCTATAGATCAATTTCTATACTTTGACTTAATATATTCTATT
AAGGACACTAAGTTAGGGAATTATGATAATGTTCGAGTCGAATTTAAAAACAAAGATTTA
GCTGATAAATACAAAGATAAATACGTAGATGTGTTTGGAGCTAATTATTATTATCAATGT
TATTTTTCTAAAAAAACGAATGATATTAATTCGCATCAAACTGACAAACGAAAAACTTGT
ATGTATGGTGGTGTAACTGAGCATAATGGAAACCAATTAGATAAATATAGAAGTATTACT
GTTCGGGTATTTGAAGATGGTAAAAATTTATTATCTTTTGACGTACAAACTAATAAGAAA
AAGGTGACTGCTCAAGAATTAGATTACCTAACTCGTCACTATTTGGTGAAAAATAAAAAA
CTCTATGAATTTAACAACTCGCCTTATGAAACGGGATATATTAAATTTATAGAAAATGAG
AATAGCTTTTGGTATGACATGATGCCTGCACCAGGAGATAAATTTGACCAATCTAAATAT
TTAATGATGTACAATGACAATAAAATGGTTGATTCTAAAGATGTGAAGATTGAAGTTTAT
CTTACGACAAAGAAAAAGTGA

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
1436058	Swaminathan S, Furey W, Pletcher J, Sax M: Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature. 1992 Oct 29;359(6398):801-6.
3898073	Ranelli DM, Jones CL, Johns MB, Mussey GJ, Khan SA: Molecular cloning of staphylococcal enterotoxin B gene in Escherichia coli and Staphylococcus aureus. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5850-4.
3957869	Jones CL, Khan SA: Nucleotide sequence of the enterotoxin B gene from Staphylococcus aureus. J Bacteriol. 1986 Apr;166(1):29-33.
5470821	Huang IY, Bergdoll MS: The primary structure of staphylococcal enterotoxin B. 3. The cyanogen bromide peptides of reduced and aminoethylated enterotoxin B, and the complete amino acid sequence. J Biol Chem. 1970 Jul 25;245(14):3518-25.
8152483	Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC: Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994 Apr 21;368(6473):711-8.
9514739	Papageorgiou AC, Tranter HS, Acharya KR: Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol. 1998 Mar 20;277(1):61-79.
9881971	Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, Karjalainen K, Mariuzza RA: Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity. 1998 Dec;9(6):807-16.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3547

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
31436

# Drug_Target_3_Name:
Enterotoxin type B

# Drug_Target_3_Number_of_Residues:
266

# Drug_Target_3_PDB_ID:
1D5M

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01123	Stap_Strp_toxin
PF02876	Stap_Strp_tox_C

# Drug_Target_3_Protein_Sequence:
>Enterotoxin type B precursor
MYKRLFISHVILIFALILVISTPNVLAESQPDPKPDELHKSSKFTGLMENMKVLYDDNHV
SAINVKSIDQFLYFDLIYSIKDTKLGNYDNVRVEFKNKDLADKYKDKYVDVFGANYYYQC
YFSKKTNDINSHQTDKRKTCMYGGVTEHNGNQLDKYRSITVRVFEDGKNLLSFDVQTNKK
KVTAQELDYLTRHYLVKNKKLYEFNNSPYETGYIKFIENENSFWYDMMPAPGDKFDQSKY
LMMYNDNKMVDSKDVKIEVYLTTKKK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-27

# Drug_Target_3_Specific_Function:
Staphylococcal enterotoxins cause the intoxication staphylococcal food poisoning syndrome. The illness characterized by high fever, hypotension, diarrhea, shock, and in some cases death

# Drug_Target_3_SwissProt_ID:
P01552

# Drug_Target_3_SwissProt_Name:
ETXB_STAAU

# Drug_Target_3_Synonyms:
Enterotoxin type B precursor
SEB

# Drug_Target_3_Theoretical_pI:
8.94

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Secreted protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
D01045

# Drug_Target_4_GenBank_ID_Protein:
216784

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
nedA

# Drug_Target_4_Gene_Sequence:
>1944 bp
ATGACTGCGAATCCGTACCTCCGCCGCCTGCCCCGGCGCCGAGCCGTCAGCTTCCTGCTC
GCACCAGCGCTGGCGGCCGCCACGGTCGCCGGCGCGTCCCCCGCACAGGCCATCGCCGGG
GCACCCGTCCCGCCCGGCGGCGAGCCGCTCTACACGGAGCAGGACCTCGCCGTGAACGGC
AGGGAGGGCTTTCCGAACTACCGCATCCCAGCGCTGACCGTCACGCCCGACGGGGACCTG
CTGGCCTCGTACGACGGCCGCCCGACCGGTATCGACGCGCCCGGCCCCAACTCCATCCTC
CAACGCCGCAGCACCGACGGCGGCCGGACGTGGGGCGAGCAACAGGTCGTCAGCGCCGGC
CAGACCACCGCGCCGATCAAGGGGTTCTCCGACCCCAGCTACCTTGTCGACCGGGAAACC
GGGACCATCTTCAACTTCCACGTCTACTCCCAGCGGCAGGGCTTCGCCGGCAGCCGGCCC
GGCACCGACCCGGCAGACCCCAACGTGCTCCACGCCAACGTCGCGACCTCGACCGACGGC
GGTCTGACCTGGTCGCACCGGACCATCACGGCCGACATCACCCCGGATCCGGGCTGGCGC
AGCCGCTTCGCCGCCTCCGGCGAAGGCATCCAGCTCCGCTATGGACCCCACGCCGGTCGA
CTCATCCAGCAGTACACGATCATCAACGCTGCCGGCGCCTTCCAGGCGGTGAGCGTGTAC
AGCGACGACCACGGAAGGACCTGGCGCGCCGGCGAAGCCGTCGGGGTCGGCATGGACGAG
AACAAGACCGTGGAACTCTCCGATGGCCGGGTCCTGCTCAACAGCCGCGACTCGGCCCGC
AGCGGATACCGTAAGGTGGCCGTCTCCACTGACGGCGGCCACAGCTACGGCCCGGTGACC
ATCGACCGCGACCTCCCCGACCCGACGAACAACGCATCGATCATCCGGGCCTTCCCTGAC
GCCCCGGCCGGCTCCGCGCGGGCCAAGGTCCTGCTCTTCTCCAACGCCGCCAGCCAGACC
TCGCGCAGTCAGGGCACCATCCGGATGTCCTGCGACGATGGCCAGACCTGGCCGGTTTCG
AAGGTCTTCCAGCCCGGCTCGATGTCGTACTCCACCCTGACCGCACTGCCCGACGGCACC
TACGGGCTGCTGTACGAGCCGGGCACCGGCATCAGATACGCCAACTTCAACCTCGCCTGG
CTGGGCGGCATCTGCGCGCCCTTCACGATTCCGGATGTGGCGCTCGAGCCGGGCCAGCAG
GTCACTGTTCCGGTGGCCGTCACGAACCAGTCCGGTATCGCGGTACCGAAGCCGAGCCTT
CAGCTCGACGCATCGCCGGACTGGCAGGTTCAGGGTTCCGTCGAGCCCCTCATGCCCGGA
CGGCAGGCCAAGGGCCAGGTGACCATCACGGTTCCCGCCGGCACCACCCCCGGTCGCTAC
CGGGTCGGTGCGACGCTGCGCACCTCCGCGGGTAACGCGTCGACGACCTTCACGGTCACG
GTTGGACTGCTCGACCAGGCCCGGATGAGCATCGCGGACGTCGACAGCGAGGAGACCGCC
CGCGAAGACGGGCGGGCGAGCAACGTGATCGACGGCAACCCCTCGACGTTCTGGCACACC
GAATGGTCGCGTGCCGATGCTCCTGGCTACCCGCACCGCATCAGCCTCGACCTCGGTGGC
ACGCACACGATCAGCGGCCTCCAGTACACCCGACGGCAGAACAGCGCCAACGAGCAGGTC
GCGGACTACGAGATCTACACCAGCCTGAACGGCACGACCTGGGATGGCCCGGTTGCCAGC
GGGCGCTTCACCACGTCCCTCGCGCCGCAGCGCGCGGTCTTCCCGGCGCGGGACGCCAGG
TACATCCGGTTGGTGGCCCTCAGCGAGCAGACCGGGCACAAGTACGCCGCGGTCGCTGAG
CTGGAGGTGGAAGGCCAGCGCTGA

# Drug_Target_4_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_4_General_References:
1400240	Sakurada K, Ohta T, Hasegawa M: Cloning, expression, and characterization of the Micromonospora viridifaciens neuraminidase gene in Streptomyces lividans. J Bacteriol. 1992 Nov;174(21):6896-903.
8591030	Gaskell A, Crennell S, Taylor G: The three domains of a bacterial sialidase: a beta-propeller, an immunoglobulin module and a galactose-binding jelly-roll. Structure. 1995 Nov 15;3(11):1197-205.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3546

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
68831

# Drug_Target_4_Name:
Sialidase

# Drug_Target_4_Number_of_Residues:
647

# Drug_Target_4_PDB_ID:
1EUU

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00754	F5_F8_type_C
PF02012	BNR

# Drug_Target_4_Protein_Sequence:
>Sialidase precursor
MTANPYLRRLPRRRAVSFLLAPALAAATVAGASPAQAIAGAPVPPGGEPLYTEQDLAVNG
REGFPNYRIPALTVTPDGDLLASYDGRPTGIDAPGPNSILQRRSTDGGRTWGEQQVVSAG
QTTAPIKGFSDPSYLVDRETGTIFNFHVYSQRQGFAGSRPGTDPADPNVLHANVATSTDG
GLTWSHRTITADITPDPGWRSRFAASGEGIQLRYGPHAGRLIQQYTIINAAGAFQAVSVY
SDDHGRTWRAGEAVGVGMDENKTVELSDGRVLLNSRDSARSGYRKVAVSTDGGHSYGPVT
IDRDLPDPTNNASIIRAFPDAPAGSARAKVLLFSNAASQTSRSQGTIRMSCDDGQTWPVS
KVFQPGSMSYSTLTALPDGTYGLLYEPGTGIRYANFNLAWLGGICAPFTIPDVALEPGQQ
VTVPVAVTNQSGIAVPKPSLQLDASPDWQVQGSVEPLMPGRQAKGQVTITVPAGTTPGRY
RVGATLRTSAGNASTTFTVTVGLLDQARMSIADVDSEETAREDGRASNVIDGNPSTFWHT
EWSRADAPGYPHRISLDLGGTHTISGLQYTRRQNSANEQVADYEIYTSLNGTTWDGPVAS
GRFTTSLAPQRAVFPARDARYIRLVALSEQTGHKYAAVAELEVEGQR

# Drug_Target_4_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_4_Signals:
1-37

# Drug_Target_4_Specific_Function:
To release sialic acids for use as carbon and energy sources for this non-pathogenic bacterium while in pathogenic microorganisms, sialidases have been suggested to be pathogenic factors

# Drug_Target_4_SwissProt_ID:
Q02834

# Drug_Target_4_SwissProt_Name:
NANH_MICVI

# Drug_Target_4_Synonyms:
EC 3.2.1.18
Neuraminidase
Sialidase precursor

# Drug_Target_4_Theoretical_pI:
6.52

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Not Available

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
Not Available

# Drug_Target_5_Gene_Sequence:
Not Available

# Drug_Target_5_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_5_General_References:
10571062	Kaneko S, Kuno A, Fujimoto Z, Shimizu D, Machida S, Sato Y, Yura K, Go M, Mizuno H, Taira K, Kusakabe I, Hayashi K: An investigation of the nature and function of module 10 in a family F/10 xylanase FXYN of Streptomyces olivaceoviridis E-86 by module shuffling with the Cex of Cellulomonas fimi and by site-directed mutagenesis. FEBS Lett. 1999 Oct 22;460(1):61-6.
11829503	Fujimoto Z, Kuno A, Kaneko S, Kobayashi H, Kusakabe I, Mizuno H: Crystal structures of the sugar complexes of Streptomyces olivaceoviridis E-86 xylanase: sugar binding structure of the family 13 carbohydrate binding module. J Mol Biol. 2002 Feb 8;316(1):65-78.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
5249

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
46750

# Drug_Target_5_Name:
Hydrolase

# Drug_Target_5_Number_of_Residues:
436

# Drug_Target_5_PDB_ID:
1V6X

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00331	Glyco_hydro_10
PF00652	Ricin_B_lectin

# Drug_Target_5_Protein_Sequence:
>Hydrolase
AESTLGAAAAQSGRYFGTAIASGKLGDSAYTTIASREFNMVTAENEMKIDATEPQRGQFN
FSAGDRVYNWAVQNGKQVRGHTLAWHSQQPGWMQSLSGSTLRQAMIDHINGVMGHYKGKI
AQWDVVNEAFSDDGSGGRRDSNLQRTGNDWIEVAFRTARAADPAAKLCYNDYNIENWTWA
KTQGVYNMVRDFKQRGVPIDCVGFQSHFNSGSPYNSNFRTTLQNFAALGVDVAITELDIQ
GASSSTYAAVTNDCLAVSRCLGITVWGVRDTDSWRSGDTPLLFNGDGSKKAAYTAVLNAL
NGGSSTPPPSGGGQIKGVGSGRCLDVPNASTTDGTQVQLYDCHSATNQQWTYTDAGELRV
YGDKCLDAAGTGNGTKVQIYSCWGGDNQKWRLNSDGSIVGVQSGLCLDAVGGGTANGTLI
QLYSCSNGSNQRWTRT

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q7SI98

# Drug_Target_5_SwissProt_Name:
Q7SI98_STROI

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
6.50

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
D50685

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
TCTS-154

# Drug_Target_6_Gene_Sequence:
>3183 bp
ATGGGGAAAACAGTCGTTGGGGCCAGTAGGATGTTCTGGCTAATGTTTTTCGTGCCGCTT
CTTCTTGCGCTCTGCCCCAGCGAGCCCGCGCATGCCCTGGCACCCGGATCGAGCCGAGTT
GAGCTGTTTAAGCGGCAAAGCTCGAAGGTGCCATTTGAAAAGGGCGGCAAAGTCACCGAG
CGGGTTGTCCACTCGTTCCGCCTCCCCGCCCTTGTTAATGTGGACGGGGTGATGGTTGCC
ATCGCGGACGCTCGCTACGAAACATCCAATGACAACTCCCTCATTGATACGGTGGCGAAG
TACAGCGTGGACGATGGGGAGACGTGGGAGACCCAAATTGCCATCAAGAACAGTCGTGCA
TCGTCTGTTTCTCGTGTGGTGGATCCCACAGTGATTGTGAAGGGCAACAAGCTTTACGTC
CTGGTTGGAAGCTACAACAGTTCGAGGAGCTACTGGACGTCGCATGGTGATGCGAGAGAC
TGGGATATTCTGCTTGCCGTTGGTGAGGTCACGAAGTCCACTGCGGGCGGCAAGATAACT
GCGAGTATCAAATGGGGGAGCCCCGTGTCACTGAAGGAATTTTTCCCGGCGGAAATGGAA
GGAATGCACACAAATCAATTTCTTGGCGGTGCAGGTGTTGCCATTGTGGCGTCCAACGGG
AATCTTGTGTACCCTGTGCAGGTTACGAACAAAAAGAAGCAAGTTTTTTCCAAGATCTTC
TACTCGGAAGACGAGGGCAAGACGTGGAAGTTTGGGGAGGGTAGGAGTGATTTTGGCTGC
TCTGAACCTGTGGCCCTTGAGTGGGAGGGGAAGCTCATCATAAACACTCGAGTTGACTAT
CGCCGCCGTCTGGTGTACGAGTCCAGTGACATGGGGAATTCGTGGGTGGAGGCTGTCGGC
ACGCTCTCACGTGTGTGGGGCCCCTCACCAAAATCGAACCAGCCCGGCAGTCAGAGCAGC
TTCACTGCCGTGACCATCGAGGGAATGCGTGTTATGCTCTTCACACACCCGCTGAATTTT
AAGGGAAGGTGGCTGCGCGACCGACTGAACCTCTGGCTGACGGATAACCAGCGCATTTAT
AACGTTGGGCAAGTATCCATTGGTGATGAAAATTCCGCCTACAGCTCCGTCCTGTACAAG
GATGATAAGCTGTACTGTTTGCATGAGATCAACAGTAACGAGGTGTACAGCCTTGTTTTT
GCGCGCCTGGTTGGCGAGCTACGGATCATTAAATCAGTGCTGCAGTCCTGGAAGAATTGG
GACAGCCACCTGTCCAGCATTTGCACCCCTGCTGATCCAGCCGCTTCGTCGTCAGAGCGT
GGTTGTGGTCCCGCTGTCACCACGGTTGGTCTTGTTGGCTTTTTGTCGCACAGTGCCACC
AAAACCGAATGGGAGGATGCGTACCGCTGCGTCAACGCAAGCACGGCAAATGCGGAGAGG
GTTCCGAACGGTTTGAAGTTTGCGGGGGTTGGCGGAGGGGCGCTTTGGCCGGTGAGCCAG
CAGGGGCAGAATCAACGGTATCACTTTGCAAACCACGCGTTCACGCTGGTGGCGTCGGTG
ACGATTCACGAGGTTCCGAGCGTCGCGAGTCCTTTGCTGGGTGCGAGCCTGGACTCTTCT
GGTGGCAAAAAACTCCTGGGGCTCTCGTACGACGAGAAGCACCAGTGGCAGCCAATATAC
GGATCAACGCCGGTGACGCCGACCGGATCGTGGGAGATGGGTAAGAGGTACCACGTGGTT
CTTACGATGGCGAATAAAATTGGTTCGGTGTACATTGATGGAGAACCTCTGGAGGGTTCA
GGGCAGACCGTTGTGCCAGACGGGAGGACGCCTGACATCTCCCACTTCTACGTTGGCGGG
TATGGAAGGAGTGATATGCCAACCATAAGCCACGTGACGGTGAATAATGTTCTTCTTTAC
AACCGTCAGCTGAATGCCGAGGAGATCAGGACCTTGTTCTTGAGCCAGGACCTGATTGGC
ACGGAAGCACACATGGGCAGCAGCAGCGGCAGCAGTGCCCACAGTACGCCCTCAACTCCC
GCTGACAACGGTGCCCACAGTACGCCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCGACTCCCGGTGACAGCAGTGCCCACAGTACGCCCTCAACTCCC
GCTGACAACGGTGCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACG
CCCTCGACTCCCGCTGACAACGGTGCCCACAGTACGCCCTCAACTCCCGCTGACAACGGT
GCCCACAGTACGCCCTCGACTCCCGGTGACAACGGTGCCCACAGTACGCCCTCGACTCCC
GGTGACAGCAGTGCCCACAGTACGCCCTCAACTCCCGCTGACAACGGTGCCCACAGTACG
CCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACGCCCTCGACTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAATGCCCACAGTACGCCCTCGACTCCC
GCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGTGCCCACAGTACG
CCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAACGGTGCCCACAGTACGCCCTCAGCTCCC
GGTGACAGCAATGCCCACAGTACGCCCTCGACTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAACTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGGTGACAACGGT
GCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACGCCCTCAATTCCC
GGTGACAGCAGTGCCCACAGTACGCCCTCAGCTCCCGCTGACAGCAGTGCCCACAGTACG
CCCTCAGCTCCCGGTGACAACGGTGCCCACAGTACGCCCTCGACTCCCGCTGACAACGGC
GCTAATGGTACGGTTTTGATTTTGCACGATGGCGCTGCATTTTCGGCCTTTTCGGGCGGA
GGGCTTCTTTTGTGTGCGGGTGCTTTGCTGCTGCACGTGTTCGTTATGGCAGTTTTTTTC
TGA

# Drug_Target_6_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_6_General_References:
12419220	Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM: The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell. 2002 Oct;10(4):757-68.
1396577	Uemura H, Schenkman S, Nussenzweig V, Eichinger D: Only some members of a gene family in Trypanosoma cruzi encode proteins that express both trans-sialidase and neuraminidase activities. EMBO J. 1992 Nov;11(11):3837-44.
8844669	Smith LE, Uemura H, Eichinger D: Isolation and expression of an open reading frame encoding sialidase from Trypanosoma rangeli. Mol Biochem Parasitol. 1996 Jul;79(1):21-33.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
5481

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
110104

# Drug_Target_6_Name:
Trans-sialidase

# Drug_Target_6_Number_of_Residues:
1060

# Drug_Target_6_PDB_ID:
1S0K

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF02012	BNR

# Drug_Target_6_Protein_Sequence:
>Trans-sialidase
MGKTVVGASRMFWLMFFVPLLLALCPSEPAHALAPGSSRVELFKRQSSKVPFEKGGKVTE
RVVHSFRLPALVNVDGVMVAIADARYETSNDNSLIDTVAKYSVDDGETWETQIAIKNSRA
SSVSRVVDPTVIVKGNKLYVLVGSYNSSRSYWTSHGDARDWDILLAVGEVTKSTAGGKIT
ASIKWGSPVSLKEFFPAEMEGMHTNQFLGGAGVAIVASNGNLVYPVQVTNKKKQVFSKIF
YSEDEGKTWKFGEGRSDFGCSEPVALEWEGKLIINTRVDYRRRLVYESSDMGNSWVEAVG
TLSRVWGPSPKSNQPGSQSSFTAVTIEGMRVMLFTHPLNFKGRWLRDRLNLWLTDNQRIY
NVGQVSIGDENSAYSSVLYKDDKLYCLHEINSNEVYSLVFARLVGELRIIKSVLQSWKNW
DSHLSSICTPADPAASSSERGCGPAVTTVGLVGFLSHSATKTEWEDAYRCVNASTANAER
VPNGLKFAGVGGGALWPVSQQGQNQRYHFANHAFTLVASVTIHEVPSVASPLLGASLDSS
GGKKLLGLSYDEKHQWQPIYGSTPVTPTGSWEMGKRYHVVLTMANKIGSVYIDGEPLEGS
GQTVVPDGRTPDISHFYVGGYGRSDMPTISHVTVNNVLLYNRQLNAEEIRTLFLSQDLIG
TEAHMGSSSGSSAHSTPSTPADNGAHSTPSTPADSSAHSTPSTPADSSAHSTPSAPGDNG
AHSTPSTPGDSSAHSTPSTPADNGAHSTPSAPADSNAHSTPSTPADNGAHSTPSTPADNG
AHSTPSTPGDNGAHSTPSTPGDSSAHSTPSTPADNGAHSTPSAPADSNAHSTPSTPGDNG
AHSTPSAPADSNAHSTPSTPADSSAHSTPSAPGDNGAHSTPSAPADSSAHSTPSAPGDNG
AHSTPSAPADNGAHSTPSAPGDSNAHSTPSTPADSSAHSTPSTPADSSAHSTPSAPGDNG
AHSTPSAPADSSAHSTPSIPGDSSAHSTPSAPADSSAHSTPSAPGDNGAHSTPSTPADNG
ANGTVLILHDGAAFSAFSGGGLLLCAGALLLHVFVMAVFF

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
Q26964

# Drug_Target_6_SwissProt_Name:
Q26964_TRYCR

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
6.27

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Secreted protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
M64551

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
xlnA

# Drug_Target_7_Gene_Sequence:
>1434 bp
ATGGGCTCCTACGCCCTTCCCAGATCAGGTGTCCGCAGGAGCATTCGCGTCCTGCTGCTG
GCGCTGGTCGTCGGCGTACTCGGCACGGCCACCGCACTGATCGCGCCGCCGGGGGCACAC
GCCGCCGAGAGCACGCTCGGCGCCGCGGCGGCGCAGAGCGGCCGCTACTTCGGCACCGCC
ATCGCCTCGGGCAGGCTGAGCGACTCGACGTACACGTCGATCGCGGGCCGTGAGTTCAAC
ATGGTGACGGCCGAGAACGAGATGAAGATCGACGCCACCGAACCGCAGCGGGGCCAGTTC
AACTTCAGCTCCGCCGACCGCGTCTACAACTGGGCGGTGCAGAACGGCAAGCAGGTGCGC
GGCCACACCCTGGCCTGGCACTCCCAGCAGCCCGGCTGGATGCAGAGCCTCAGCGGCAGC
GCGCTGCGCCAGGCGATGATCGACCACATCAACGGCGTGATGGCCCACTACAAGGGCAAG
ATCGTCCAGTGGGACGTCGTGAACGAGGCCTTCGCCGACGGCAGTTCGGGAGCGCGGCGG
GACTCCAACCTGCAACGCAGCGGCAACGACTGGATCGAGGTCGCCTTCCGCACCGCGCGC
GCCGCCGACCCGTCCGCCAAGCTCTGCTACAACGACTACAACGTCGAGAACTGGACCTGG
GCCAAGACCCAGGCCATGTACAACATGGTGCGGGACTTCAAGCAGCGCGGCGTGCCGATC
GACTGCGTCGGCTTCCAGTCGCACTTCAACAGCGGCAGCCCCTACAACAGCAACTTCCGC
ACCACACTGCAGAACTTCGCCGCCCTCGGCGTCGACGTGGCCATCACCGAGCTGGACATC
CAGGGCGCCCCGGCCTCGACCTACGCCAACGTGACCAACGACTGCCTGGCCGTCTCGCGC
TGCCTCGGCATCACCGTCTGGGGTGTGCGCGACAGCGACTCCTGGCGGTCGGAGCAGACG
CCGTTGCTGTTCAACAACGACGGCAGCAAGAAGGCCGCGTACACCGCCGTCCTCGACGCA
CTCAACGGCGGCGACTCCTCGGAGCCCCCCGCGGACGGGGGACAGATCAAGGGCGTCGGT
TCGGGCCGCTGCCTCGACGTGCCCGACGCCAGCACCTCCGACGGCACCCAGCTCCAGCTG
TGGGACTGCCACAGCGGCACCAACCAGCAGTGGGCCGCCACTGACGCGGGCGAGCTCAGG
GTCTACGGCGACAAGTGCCTGGACGCCGCAGGCACCAGCAACGGCTCCAAGGTCCAGATC
TACAGCTGCTGGGGCGGCGACAACCAGAAGTGGCGCCTCAACTCCGACGGGTCCGTCGTC
GGCGTCCAGTCCGGCCTCTGCCTCGACGCCGTCGGGAACGGCACGGCCAACGGCACCCTG
ATCCAGCTGTACACCTGCTCCAACGGCAGCAACCAACGCTGGACCCGCACCTGA

# Drug_Target_7_General_Function:
Involved in hydrolase activity, hydrolyzing O-glycosyl compounds

# Drug_Target_7_General_References:
1743521	Shareck F, Roy C, Yaguchi M, Morosoli R, Kluepfel D: Sequences of three genes specifying xylanases in Streptomyces lividans. Gene. 1991 Oct 30;107(1):75-82.
8063693	Derewenda U, Swenson L, Green R, Wei Y, Morosoli R, Shareck F, Kluepfel D, Derewenda ZS: Crystal structure, at 2.6-A resolution, of the Streptomyces lividans xylanase A, a member of the F family of beta-1,4-D-glycanases. J Biol Chem. 1994 Aug 19;269(33):20811-4.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
4715

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
51163

# Drug_Target_7_Name:
Endo-1,4-beta-xylanase A

# Drug_Target_7_Number_of_Residues:
477

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00331	Glyco_hydro_10
PF00652	Ricin_B_lectin

# Drug_Target_7_Protein_Sequence:
>Endo-1,4-beta-xylanase A
MGSYALPRSGVRRSIRVLLLALVVGVLGTATALIAPPGAHAAESTLGAAAAQSGRYFGTA
IASGRLSDSTYTSIAGREFNMVTAENEMKIDATEPQRGQFNFSSADRVYNWAVQNGKQVR
GHTLAWHSQQPGWMQSLSGSALRQAMIDHINGVMAHYKGKIVQWDVVNEAFADGSSGARR
DSNLQRSGNDWIEVAFRTARAADPSAKLCYNDYNVENWTWAKTQAMYNMVRDFKQRGVPI
DCVGFQSHFNSGSPYNSNFRTTLQNFAALGVDVAITELDIQGAPASTYANVTNDCLAVSR
CLGITVWGVRDSDSWRSEQTPLLFNNDGSKKAAYTAVLDALNGGDSSEPPADGGQIKGVG
SGRCLDVPDASTSDGTQLQLWDCHSGTNQQWAATDAGELRVYGDKCLDAAGTSNGSKVQI
YSCWGGDNQKWRLNSDGSVVGVQSGLCLDAVGNGTANGTLIQLYTCSNGSNQRWTRT

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-41

# Drug_Target_7_Specific_Function:
Contributes to hydrolyze hemicellulose, the major component of plant cell-walls. XLNA and XLNB seem to act sequentially on the substrate to yield xylobiose and xylose as carbon sources

# Drug_Target_7_SwissProt_ID:
P26514

# Drug_Target_7_SwissProt_Name:
XYNA_STRLI

# Drug_Target_7_Synonyms:
1,4- beta-D-xylan xylanohydrolase A
EC 3.2.1.8
Endo-1,4-beta-xylanase A precursor
Xylanase A

# Drug_Target_7_Theoretical_pI:
6.61

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
J01636

# Drug_Target_8_GenBank_ID_Protein:
146577

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
lacZ

# Drug_Target_8_Gene_Sequence:
>3075 bp
ATGACCATGATTACGGATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCT
GGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGC
GAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGC
TTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCT
GAGGCCGATACTGTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATC
TACACCAACGTAACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCG
ACGGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACG
CGAATTATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTC
GGTTACGGCCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCC
GGAGAAAACCGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGAT
CAGGATATGTGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACT
ACACAAATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTA
CTGGAGGCTGAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCT
TTATGGCAGGGTGAAACGCAGGTCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATC
GATGAGCGTGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAA
CTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGAC
GGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGAAAAT
GGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCAT
CATCCTCTGCATGGTCAGGTCATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATG
AAGCAGAACAACTTTAACGCCGTGCGCTGTTCGCATTATCCGAACCATCCGCTGTGGTAC
ACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACGGC
ATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGC
GTAACGCGAATGGTGCAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGG
AATGAATCAGGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTCGAT
CCTTCCCGCCCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATT
TGCCCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCC
ATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCC
CACGCGATGGGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCGTTTCGTCAGTAT
CCCCGTTTACAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGAT
GAAAACGGCAACCCGTGGTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGC
CAGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAA
GCAAAACACCAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACC
AGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGAT
GGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTAAACAGTTG
ATTGAACTGCCTGAACTACCGCAGCCGGAGAGCGCCGGGCAACTCTGGCTCACAGTACGC
GTAGTGCAACCGAACGCGACCGCATGGTCAGAAGCCGGGCACATCAGCGCCTGGCAGCAG
TGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCGTCCCACGCCATCCCGCAT
CTGACCACCAGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATTTAAC
CGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAACTGCTGACGCCG
CTGCGCGATCAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACC
CGCATTGACCCTAACGCCTGGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGAA
GCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGCT
CACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGGAAAACCTACCGGATTGAT
GGTAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCG
GCGCGGATTGGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAAACTGGCTCGGA
TTAGGGCCGCAAGAAAACTATCCCGACCGCCTTACTGCCGCCTGTTTTGACCGCTGGGAT
CTGCCATTGTCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGC
GGGACGCGCGAATTGAATTATGGCCCACACCAGTGGCGCGGCGACTTCCAGTTCAACATC
AGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAA
GAAGGCACATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCTGG
AGCCCGTCAGTATCGGCGGAATTCCAGCTGAGCGCCGGTCGCTACCATTACCAGTTGGTC
TGGTGTCAAAAATAA

# Drug_Target_8_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_8_General_References:
11732897	Juers DH, Heightman TD, Vasella A, McCarter JD, Mackenzie L, Withers SG, Matthews BW: A structural view of the action of Escherichia coli (lacZ) beta-galactosidase. Biochemistry. 2001 Dec 11;40(49):14781-94.
1350782	Gebler JC, Aebersold R, Withers SG: Glu-537, not Glu-461, is the nucleophile in the active site of (lac Z) beta-galactosidase from Escherichia coli. J Biol Chem. 1992 Jun 5;267(16):11126-30.
6246435	Calos MP, Miller JH: Molecular consequences of deletion formation mediated by the transposon Tn9. Nature. 1980 May 1;285(5759):38-41.
6313347	Kalnins A, Otto K, Ruther U, Muller-Hill B: Sequence of the lacZ gene of Escherichia coli. EMBO J. 1983;2(4):593-7.
6411710	Fowler AV, Smith PJ: The active site regions of lacZ and ebg beta-galactosidases are homologous. J Biol Chem. 1983 Sep 10;258(17):10204-7.
6420154	Herrchen M, Legler G: Identification of an essential carboxylate group at the active site of lacZ beta-galactosidase from Escherichia coli. Eur J Biochem. 1984 Feb 1;138(3):527-31.
6444453	Buchel DE, Gronenborn B, Muller-Hill B: Sequence of the lactose permease gene. Nature. 1980 Feb 7;283(5747):541-5.
8008071	Jacobson RH, Zhang XJ, DuBose RF, Matthews BW: Three-dimensional structure of beta-galactosidase from E. coli. Nature. 1994 Jun 30;369(6483):761-6.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
97298	Fowler AV, Zabin I: Amino acid sequence of beta-galactosidase. XI. Peptide ordering procedures and the complete sequence. J Biol Chem. 1978 Aug 10;253(15):5521-5.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2592

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
116484

# Drug_Target_8_Name:
Beta-galactosidase

# Drug_Target_8_Number_of_Residues:
1024

# Drug_Target_8_PDB_ID:
1JZ2

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00703	Glyco_hydro_2
PF02836	Glyco_hydro_2_C
PF02837	Glyco_hydro_2_N
PF02929	Bgal_small_N

# Drug_Target_8_Protein_Sequence:
>Beta-galactosidase
MTMITDSLAVVLQRRDWENPGVTQLNRLAAHPPFASWRNSEEARTDRPSQQLRSLNGEWR
FAWFPAPEAVPESWLECDLPEADTVVVPSNWQMHGYDAPIYTNVTYPITVNPPFVPTENP
TGCYSLTFNVDESWLQEGQTRIIFDGVNSAFHLWCNGRWVGYGQDSRLPSEFDLSAFLRA
GENRLAVMVLRWSDGSYLEDQDMWRMSGIFRDVSLLHKPTTQISDFHVATRFNDDFSRAV
LEAEVQMCGELRDYLRVTVSLWQGETQVASGTAPFGGEIIDERGGYADRVTLRLNVENPK
LWSAEIPNLYRAVVELHTADGTLIEAEACDVGFREVRIENGLLLLNGKPLLIRGVNRHEH
HPLHGQVMDEQTMVQDILLMKQNNFNAVRCSHYPNHPLWYTLCDRYGLYVVDEANIETHG
MVPMNRLTDDPRWLPAMSERVTRMVQRDRNHPSVIIWSLGNESGHGANHDALYRWIKSVD
PSRPVQYEGGGADTTATDIICPMYARVDEDQPFPAVPKWSIKKWLSLPGETRPLILCEYA
HAMGNSLGGFAKYWQAFRQYPRLQGGFVWDWVDQSLIKYDENGNPWSAYGGDFGDTPNDR
QFCMNGLVFADRTPHPALTEAKHQQQFFQFRLSGQTIEVTSEYLFRHSDNELLHWMVALD
GKPLASGEVPLDVAPQGKQLIELPELPQPESAGQLWLTVRVVQPNATAWSEAGHISAWQQ
WRLAENLSVTLPAASHAIPHLTTSEMDFCIELGNKRWQFNRQSGFLSQMWIGDKKQLLTP
LRDQFTRAPLDNDIGVSEATRIDPNAWVERWKAAGHYQAEAALLQCTADTLADAVLITTA
HAWQHQGKTLFISRKTYRIDGSGQMAITVDVEVASDTPHPARIGLNCQLAQVAERVNWLG
LGPQENYPDRLTAACFDRWDLPLSDMYTPYVFPSENGLRCGTRELNYGPHQWRGDFQFNI
SRYSQQQLMETSHRHLLHAEEGTWLNIDGFHMGIGGDDSWSPSVSAEFQLSAGRYHYQLV
WCQK

# Drug_Target_8_Reaction:
Hydrolysis of terminal non-reducing beta-D-galactose residues in beta-D-galactosides ALL_REAC (other) R01105 R01678 R01679 R03355 R03616 R04633 R04783 R05112 R05994(G) R06010(G) R06098(G) R06099(G) R06111(G) R06144(G) R06202(G) R07807(G)

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Hydrolysis of terminal non-reducing beta-D- galactose residues in beta-D-galactosides

# Drug_Target_8_SwissProt_ID:
P00722

# Drug_Target_8_SwissProt_Name:
BGAL_ECOLI

# Drug_Target_8_Synonyms:
EC 3.2.1.23
Lactase

# Drug_Target_8_Theoretical_pI:
5.20

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
X04436

# Drug_Target_9_GenBank_ID_Protein:
40770

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
tetX

# Drug_Target_9_Gene_Sequence:
>3948 bp
ATGCCAATAACCATAAATAATTTTAGATATAGTGATCCTGTTAATAATGATACAATTATT
ATGATGGAGCCACCATACTGTAAGGGTCTAGATATCTATTATAAGGCTTTCAAAATAACA
GATCGTATTTGGATAGTGCCGGAAAGGTATGAATTTGGGACAAAACCTGAAGATTTTAAC
CCACCATCTTCATTAATAGAAGGTGCATCTGAGTATTACGATCCAAATTATTTAAGGACT
GATTCTGATAAAGATAGATTTTTACAAACCATGGTAAAACTGTTTAACAGAATTAAAAAC
AATGTAGCAGGTGAAGCCTTATTAGATAAGATAATAAATGCCATACCTTACCTTGGAAAT
TCATATTCCTTACTAGACAAGTTTGATACAAACTCTAATTCAGTATCTTTTAATTTATTA
GAACAAGACCCCAGTGGAGCAACTACAAAATCAGCAATGCTGACAAATTTAATAATATTT
GGACCTGGGCCTGTTTTAAATAAAAATGAGGTTAGAGGTATTGTATTGAGGGTAGATAAT
AAAAATTACTTCCCATGTAGAGATGGTTTTGGCTCAATAATGCAAATGGCATTTTGCCCA
GAATATGTACCTACCTTTGATAATGTAATAGAAAATATTACGTCACTCACTATTGGCAAA
AGCAAATATTTTCAAGATCCAGCATTACTATTAATGCACGAACTTATACATGTACTACAT
GGTTTATACGGAATGCAGGTATCAAGCCATGAAATTATTCCATCCAAACAAGAAATTTAT
ATGCAGCATACATATCCAATAAGTGCTGAAGAACTATTCACTTTTGGCGGACAGGATGCT
AATCTTATAAGTATTGATATAAAAAACGATTTATATGAAAAAACTTTAAATGATTATAAA
GCTATAGCTAACAAACTTAGTCAAGTCACTAGCTGCAATGATCCCAACATTGATATTGAT
AGCTACAAACAAATATATCAACAAAAATATCAATTCGATAAAGATAGCAATGGACAATAT
ATTGTAAATGAGGATAAATTTCAGATACTATATAATAGCATAATGTATGGTTTTACAGAG
ATTGAATTGGGAAAAAAATTTAATATAAAAACTAGACTTTCTTATTTTAGTATGAATCAT
GACCCTGTAAAAATTCCAAATTTATTAGATGATACAATTTACAATGATACAGAAGGATTT
AATATAGAAAGCAAAGATCTGAAATCTGAATATAAAGGACAAAATATGAGGGTAAATACA
AATGCTTTTAGAAATGTTGATGGATCAGGCCTAGTTTCAAAACTTATTGGCTTATGTAAA
AAAATTATACCACCAACAAATATAAGAGAAAATTTATATAATAGAACTGCATCATTAACA
GATTTAGGAGGAGAATTATGTATAAAAATTAAAAATGAAGATTTAACTTTTATAGCTGAA
AAAAATAGCTTTTCAGAAGAACCATTTCAAGATGAAATAGTTAGTTATAATACAAAAAAT
AAACCATTAAATTTTAATTATTCGCTAGATAAAATTATTGTAGATTATAATCTACAAAGT
AAAATTACATTACCTAATGATAGGACAACCCCAGTTACAAAAGGAATTCCATATGCTCCA
GAATATAAAAGTAATGCTGCAAGTACAATAGAAATACATAATATTGATGACAATACAATA
TATCAATATTTGTATGCTCAAAAATCTCCTACAACTCTACAAAGAATAACTATGACTAAT
TCTGTTGATGACGCATTAATAAATTCCACCAAAATATATTCATATTTTCCATCTGTAATC
AGTAAAGTTAACCAAGGTGCACAAGGAATTTTATTCTTACAGTGGGTGAGAGATATAATT
GATGATTTTACCAATGAATCTTCACAAAAAACTACTATTGATAAAATTTCAGATGTATCC
ACTATTGTTCCTTATATAGGACCCGCATTAAACATTGTAAAACAAGGCTATGAGGGAAAC
TTTATAGGCGCTTTAGAAACTACCGGAGTGGTTTTATTATTAGAATATATTCCAGAAATT
ACTTTACCAGTAATTGCAGCTTTATCTATAGCAGAAAGTAGCACACAAAAAGAAAAGATA
ATAAAAACAATAGATAACTTTTTAGAAAAAAGATATGAAAAATGGATTGAAGTATATAAA
CTAGTAAAAGCAAAATGGTTAGGCACAGTTAATACGCAATTCCAAAAAAGAAGTTATCAA
ATGTATAGATCTTTAGAATATCAAGTAGATGCAATAAAAAAAATAATAGACTATGAATAT
AAAATATATTCAGGACCTGATAAGGAACAAATTGCCGACGAAATTAATAATCTGAAAAAC
AAACTTGAAGAAAAGGCTAATAAAGCAATGATAAACATAAATATATTTATGAGGGAAAGT
TCTAGATCATTTTTAGTTAATCAAATGATTAACGAAGCTAAAAAGCAGTTATTAGAGTTT
GATACTCAAAGCAAAAATATTTTAATGCAGTATATAAAAGCAAATTCTAAATTTATAGGT
ATAACTGAACTAAAAAAATTAGAATCAAAAATAAACAAAGTTTTTTCAACACCAATTCCA
TTTTCTTATTCTAAAAATCTGGATTGTTGGGTTGATAATGAAGAAGATATAGATGTTATA
TTAAAAAAGAGTACAATTTTAAATTTAGATATTAATAATGATATTATATCAGATATATCT
GGGTTTAATTCATCTGTAATAACATATCCAGATGCTCAATTGGTGCCCGGAATAAATGGC
AAAGCAATACATTTAGTAAACAATGAATCTTCTGAAGTTATAGTGCATAAAGCTATGGAT
ATTGAATATAATGATATGTTTAATAATTTTACCGTTAGCTTTTGGTTGAGGGTTCCTAAA
GTATCTGCTAGTCATTTAGAACAATATGGCACAAATGAGTATTCAATAATTAGCTCTATG
AAAAAACATAGTCTATCAATAGGATCTGGTTGGAGTGTATCACTTAAAGGTAATAACTTA
ATATGGACTTTAAAAGATTCCGCGGGAGAAGTTAGACAAATAACTTTTAGGGATTTACCT
GATAAATTTAATGCTTATTTAGCAAATAAATGGGTTTTTATAACTATTACTAATGATAGA
TTATCTTCTGCTAATTTGTATATAAATGGAGTACTTATGGGAAGTGCAGAAATTACTGGT
TTAGGAGCTATTAGAGAGGATAATAATATAACATTAAAACTAGATAGATGTAATAATAAT
AATCAATACGTTTCTATTGATAAATTTAGGATATTTTGCAAAGCATTAAATCCAAAAGAG
ATTGAAAAATTATACACAAGTTATTTATCTATAACCTTTTTAAGAGACTTCTGGGGAAAC
CCTTTACGATATGATACAGAATATTATTTAATACCAGTAGCTTCTAGTTCTAAAGATGTT
CAATTGAAAAATATAACAGATTATATGTATTTGACAAATGCGCCATCGTATACTAACGGA
AAATTGAATATATATTATAGAAGGTTATATAATGGACTAAAATTTATTATAAAAAGATAT
ACACCTAATAATGAAATAGATTCTTTTGTTAAATCAGGTGATTTTATTAAATTATATGTA
TCATATAACAATAATGAGCACATTGTAGGTTATCCGAAAGATGGAAATGCCTTTAATAAT
CTTGATAGAATTCTAAGAGTAGGTTATAATGCCCCAGGTATCCCTCTTTATAAAAAAATG
GAAGCAGTAAAATTGCGTGATTTAAAAACCTATTCTGTACAACTTAAATTATATGATGAT
AAAAATGCATCTTTAGGACTAGTAGGTACCCATAATGGTCAAATAGGCAACGATCCAAAT
AGGGATATATTAATTGCAAGCAACTGGTACTTTAATCATTTAAAAGATAAAATTTTAGGA
TGTGATTGGTACTTTGTACCTACAGATGAAGGATGGACAAATGATTAA

# Drug_Target_9_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_9_General_References:
12552129	Bruggemann H, Baumer S, Fricke WF, Wiezer A, Liesegang H, Decker I, Herzberg C, Martinez-Arias R, Merkl R, Henne A, Gottschalk G: The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1316-21. Epub 2003 Jan 27.
1331807	Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992 Oct 29;359(6398):832-5.
1396558	Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C: Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992 Oct;11(10):3577-83.
1935979	Krieglstein KG, Henschen AH, Weller U, Habermann E: Limited proteolysis of tetanus toxin. Relation to activity and identification of cleavage sites. Eur J Biochem. 1991 Nov 15;202(1):41-51.
2108021	Krieglstein K, Henschen A, Weller U, Habermann E: Arrangement of disulfide bridges and positions of sulfhydryl groups in tetanus toxin. Eur J Biochem. 1990 Feb 22;188(1):39-45.
3510187	Fairweather NF, Lyness VA, Pickard DJ, Allen G, Thomson RO: Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol. 1986 Jan;165(1):21-7.
3536478	Eisel U, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Habermann E, Niemann H: Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J. 1986 Oct;5(10):2495-502.
3774547	Fairweather NF, Lyness VA: The complete nucleotide sequence of tetanus toxin. Nucleic Acids Res. 1986 Oct 10;14(19):7809-12.
9334741	Umland TC, Wingert LM, Swaminathan S, Furey WF, Schmidt JJ, Sax M: Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat Struct Biol. 1997 Oct;4(10):788-92.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
2570

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
150684

# Drug_Target_9_Name:
Tetanus toxin

# Drug_Target_9_Number_of_Residues:
1315

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF01742	Peptidase_M27
PF07951	Toxin_R_bind_C
PF07952	Toxin_trans
PF07953	Toxin_R_bind_N

# Drug_Target_9_Protein_Sequence:
>Tetanus toxin precursor
MPITINNFRYSDPVNNDTIIMMEPPYCKGLDIYYKAFKITDRIWIVPERYEFGTKPEDFN
PPSSLIEGASEYYDPNYLRTDSDKDRFLQTMVKLFNRIKNNVAGEALLDKIINAIPYLGN
SYSLLDKFDTNSNSVSFNLLEQDPSGATTKSAMLTNLIIFGPGPVLNKNEVRGIVLRVDN
KNYFPCRDGFGSIMQMAFCPEYVPTFDNVIENITSLTIGKSKYFQDPALLLMHELIHVLH
GLYGMQVSSHEIIPSKQEIYMQHTYPISAEELFTFGGQDANLISIDIKNDLYEKTLNDYK
AIANKLSQVTSCNDPNIDIDSYKQIYQQKYQFDKDSNGQYIVNEDKFQILYNSIMYGFTE
IELGKKFNIKTRLSYFSMNHDPVKIPNLLDDTIYNDTEGFNIESKDLKSEYKGQNMRVNT
NAFRNVDGSGLVSKLIGLCKKIIPPTNIRENLYNRTASLTDLGGELCIKIKNEDLTFIAE
KNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAP
EYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVI
SKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGN
FIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYK
LVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKN
KLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIG
ITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVILKKSTILNLDINNDIISDIS
GFNSSVITYPDAQLVPGINGKAIHLVNNESSEVIVHKAMDIEYNDMFNNFTVSFWLRVPK
VSASHLEQYGTNEYSIISSMKKHSLSIGSGWSVSLKGNNLIWTLKDSAGEVRQITFRDLP
DKFNAYLANKWVFITITNDRLSSANLYINGVLMGSAEITGLGAIREDNNITLKLDRCNNN
NQYVSIDKFRIFCKALNPKEIEKLYTSYLSITFLRDFWGNPLRYDTEYYLIPVASSSKDV
QLKNITDYMYLTNAPSYTNGKLNIYYRRLYNGLKFIIKRYTPNNEIDSFVKSGDFIKLYV
SYNNNEHIVGYPKDGNAFNNLDRILRVGYNAPGIPLYKKMEAVKLRDLKTYSVQLKLYDD
KNASLGLVGTHNGQIGNDPNRDILIASNWYFNHLKDKILGCDWYFVPTDEGWTND

# Drug_Target_9_Reaction:
Hydrolysis of -Gln76!Phe- bond in synaptobrevin (also known as neuronal vesicle-associated membrane protein, VAMP)

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Tetanus toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that catalyzes the hydrolysis of the '76-Gln-|-Phe- 77' bond of synaptobrevin-2

# Drug_Target_9_SwissProt_ID:
P04958

# Drug_Target_9_SwissProt_Name:
TETX_CLOTE

# Drug_Target_9_Synonyms:
EC 3.4.24.68
Tentoxylysin
Tetanus toxin precursor

# Drug_Target_9_Theoretical_pI:
5.91

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB04465
